1. A clinician is asked to design antiemetic coverage for two different patients: one starting highly emetogenic chemotherapy and one prone to severe seasickness. Applying the principle that effective antiemetic therapy targets the dominant afferent input to the vomiting center, which pairing of strategy to patient is correct?
A) Both patients are best served by the same regimen, because all nausea converges on a single common receptor
B) The chemotherapy patient should receive a muscarinic antagonist, and the seasickness patient should receive a 5-HT3 antagonist plus an NK1 antagonist
C) The chemotherapy patient should receive blockade of the chemoreceptor trigger zone and vagal afferent pathways (a 5-HT3 antagonist plus an NK1 antagonist plus dexamethasone), and the seasickness patient should receive vestibular pathway blockade (transdermal scopolamine)
D) Both patients should receive a motilin receptor agonist, because gut motility drives both forms of nausea
E) The chemotherapy patient should receive an anxiolytic for the cortical pathway, and the seasickness patient should receive an NK1 antagonist
ANSWER: C
Rationale:
Effective antiemetic therapy requires targeting the dominant input pathway for the clinical context. Chemotherapy-induced nausea is driven by the chemoreceptor trigger zone (CTZ) and gut vagal afferents (enterochromaffin cell serotonin release plus substance P signaling), so the guideline-concordant strategy is a 5-HT3 antagonist plus an NK1 antagonist plus dexamethasone. Motion sickness is driven by vestibular afferent input, which is best interrupted with a muscarinic antagonist such as transdermal scopolamine.
Option A: Option A is incorrect because the two forms of nausea arise from distinct afferent pathways and do not converge on a single receptor.
Option B: Option B is incorrect because it reverses the two strategies, assigning the vestibular drug to the chemotherapy patient and the chemo regimen to the seasickness patient.
Option D: Option D is incorrect because motilin agonists are prokinetics for gastroparesis, not the appropriate antiemetic strategy for either patient.
Option E: Option E is incorrect because the chemotherapy patient's dominant pathway is the CTZ and vagal afferents rather than the cortical anticipatory pathway, and the seasickness patient needs vestibular blockade rather than an NK1 antagonist.
2. A patient on chronic warfarin begins highly emetogenic chemotherapy with an aprepitant-and-dexamethasone-containing antiemetic regimen. Considering aprepitant's full enzymatic profile, what combined effect should the clinician anticipate?
A) Aprepitant inhibits CYP3A4, raising dexamethasone concentrations (so the dexamethasone dose is reduced), while simultaneously inducing CYP2C9, which can lower warfarin concentrations and reduce the INR (so the INR must be monitored)
B) Aprepitant inhibits both CYP3A4 and CYP2C9, raising both dexamethasone and warfarin concentrations equally
C) Aprepitant induces CYP3A4 and inhibits CYP2C9, lowering dexamethasone and raising warfarin concentrations
D) Aprepitant has no enzymatic activity, so neither dexamethasone nor warfarin dosing is affected
E) Aprepitant displaces both drugs from plasma proteins, transiently raising free concentrations of each
ANSWER: A
Rationale:
Aprepitant exerts opposite effects on two enzymes simultaneously. As a moderate CYP3A4 inhibitor, it raises plasma concentrations of the CYP3A4 substrate dexamethasone, so the dexamethasone dose is reduced by roughly half. As a CYP2C9 inducer, it can lower warfarin plasma concentrations and reduce the INR (international normalized ratio), so the INR should be monitored in patients on warfarin.
Option B: Option B is incorrect because aprepitant induces (rather than inhibits) CYP2C9, so warfarin levels fall rather than rise.
Option C: Option C is incorrect because it reverses both directions: aprepitant inhibits CYP3A4 (raising dexamethasone) and induces CYP2C9 (lowering warfarin).
Option D: Option D is incorrect because aprepitant has clinically meaningful enzymatic effects on both pathways.
Option E: Option E is incorrect because the interactions are enzymatic, not protein-binding displacement.
3. A patient with protracted vomiting has developed hypokalemia and hypomagnesemia and is about to receive intravenous ondansetron. Integrating the drug's cardiac liability with the patient's metabolic state, what is the most important consideration?
A) The electrolyte abnormalities are protective against arrhythmia, so a higher ondansetron dose is safe
B) Ondansetron's only relevant risk is constipation, so the electrolytes are irrelevant to drug selection
C) Hypokalemia and hypomagnesemia shorten the QTc, offsetting any effect of ondansetron
D) Ondansetron causes extrapyramidal symptoms that are worsened by low magnesium, so the electrolytes must be corrected first
E) Ondansetron prolongs the QTc through hERG channel blockade, and hypokalemia and hypomagnesemia independently prolong the QTc, so the combination compounds the risk of torsades de pointes; electrolytes should be corrected and the lowest effective dose used
ANSWER: E
Rationale:
Ondansetron prolongs the QTc (corrected QT interval) through cardiac hERG (human ether-a-go-go-related gene) channel blockade, and both hypokalemia and hypomagnesemia independently prolong the QTc; the combination therefore compounds the risk of torsades de pointes. The appropriate response is to correct the electrolyte abnormalities, use the lowest effective dose, and avoid exceeding the FDA single-dose ceiling.
Option A: Option A is incorrect because hypokalemia and hypomagnesemia increase, rather than reduce, arrhythmia risk.
Option B: Option B is incorrect because QTc prolongation, not constipation, is the cardiac concern that interacts with the patient's electrolyte state.
Option C: Option C is incorrect because these electrolyte abnormalities prolong rather than shorten the QTc.
Option D: Option D is incorrect because ondansetron does not cause extrapyramidal symptoms; it has no significant dopamine D2 activity.
4. A trainee proposes covering a patient receiving highly emetogenic chemotherapy with ondansetron alone. Applying the pharmacology of the acute and delayed emetic phases, why is single-agent 5-HT3 antagonist prophylaxis inadequate?
A) Because ondansetron has no antiemetic activity at all and must always be combined with a prokinetic
B) Because a 5-HT3 antagonist addresses mainly the acute, serotonin-mediated phase but does not adequately cover the delayed phase, which is driven by substance P at NK1 receptors, so an NK1 antagonist plus dexamethasone is added for full coverage
C) Because ondansetron only works for motion sickness and has no role in chemotherapy nausea
D) Because the delayed phase is also serotonin-mediated, so two different 5-HT3 antagonists must be combined
E) Because single-agent therapy fails only due to inadequate dosing, and doubling the ondansetron dose provides complete coverage
ANSWER: B
Rationale:
A 5-HT3 antagonist primarily addresses the acute phase of chemotherapy-induced nausea and vomiting (within 24 hours), which is mediated by serotonin released from enterochromaffin cells. The delayed phase (days 2 to 5) is driven by substance P acting at NK1 receptors, which a 5-HT3 antagonist does not adequately cover; this is why guideline-concordant prophylaxis for highly emetogenic chemotherapy adds an NK1 antagonist and dexamethasone.
Option A: Option A is incorrect because ondansetron is highly effective for the acute phase; the problem is incomplete coverage, not absent activity.
Option C: Option C is incorrect because ondansetron is a cornerstone of acute chemotherapy nausea prophylaxis, not solely a motion-sickness drug.
Option D: Option D is incorrect because the delayed phase is mediated by substance P at NK1 receptors, not by serotonin, so adding a second 5-HT3 antagonist would not address it.
Option E: Option E is incorrect because the gap is mechanistic (an uncovered delayed NK1-mediated phase), not simply a matter of dose escalation, and exceeding the ondansetron dose ceiling raises QTc risk.
5. A student asks why metoclopramide cannot simply be engineered to keep its prokinetic and antiemetic benefits while shedding its extrapyramidal risk. Integrating the drug's sites of action, what is the best explanation?
A) Its prokinetic effect and its extrapyramidal effect arise from entirely unrelated receptors, so they could be separated easily
B) Its extrapyramidal effect comes from hERG channel blockade, which is independent of its dopamine activity
C) Its benefits derive from 5-HT3 blockade while its toxicity derives from muscarinic blockade, two separable mechanisms
D) Both its central antiemetic benefit and its extrapyramidal toxicity arise from dopamine D2 blockade in the CNS, which the drug reaches because it crosses the blood-brain barrier, so the same property that confers central benefit also produces the toxicity
E) Its toxicity is purely idiosyncratic and unrelated to its mechanism of action
ANSWER: D
Rationale:
Metoclopramide crosses the blood-brain barrier and blocks dopamine D2 receptors in the CNS. This central D2 blockade produces both its antiemetic benefit at the chemoreceptor trigger zone and its extrapyramidal toxicity (and tardive dyskinesia) at the nigrostriatal pathway, so the same property responsible for central benefit is responsible for central toxicity. This is precisely why domperidone, which is largely excluded from the CNS, lacks the extrapyramidal effects.
Option A: Option A is incorrect because the central benefit and toxicity share the same D2 mechanism rather than arising from unrelated receptors.
Option B: Option B is incorrect because the extrapyramidal effect is dopaminergic, not a consequence of hERG channel blockade.
Option C: Option C is incorrect because metoclopramide's central effects are mediated by D2 blockade, not by separable 5-HT3 and muscarinic mechanisms.
Option E: Option E is incorrect because the toxicity is a predictable pharmacological consequence of central D2 blockade, not an idiosyncratic reaction.
6. A patient with diabetic gastroparesis on stable metoclopramide presents with an abrupt worsening of nausea and vomiting during an episode of markedly elevated blood glucose. Integrating the pathophysiology of diabetic gastroparesis with the acute effect of hyperglycemia, what best explains the deterioration and guides management?
A) Acute hyperglycemia accelerates gastric emptying, so the worsening symptoms must be from a metoclopramide overdose
B) The metoclopramide has caused tardive dyskinesia, which presents as acute vomiting
C) Acute hyperglycemia itself inhibits gastric motility and can precipitate a gastroparetic crisis, so correcting the glucose (alongside hydration and antiemetics) is central to management, in addition to the chronic interstitial-cell-of-Cajal and vagal injury underlying the baseline disease
D) The symptoms reflect a new mechanical obstruction, which is the defining feature of gastroparesis
E) Hyperglycemia has no effect on gastric motility, so the timing is coincidental
ANSWER: C
Rationale:
Diabetic gastroparesis reflects chronic injury to the interstitial cells of Cajal (the gastric pacemaker cells) and to enteric neurons and the vagus nerve, but acute hyperglycemia itself independently inhibits gastric motility and can precipitate an acute gastroparetic crisis. Correcting the glucose, along with hydration and antiemetic therapy, is therefore central to managing this deterioration, and tight glycemic control also slows progression of the underlying autonomic neuropathy.
Option A: Option A is incorrect because acute hyperglycemia inhibits, rather than accelerates, gastric emptying.
Option B: Option B is incorrect because tardive dyskinesia is a movement disorder, not an acute vomiting syndrome.
Option D: Option D is incorrect because gastroparesis is by definition delayed emptying in the absence of mechanical obstruction.
Option E: Option E is incorrect because hyperglycemia has a well-established inhibitory effect on gastric motility, making the timing causally relevant rather than coincidental.
7. In a country where domperidone is available, a clinician considers it for a gastroparesis patient who previously developed dystonia on metoclopramide but who also has a family history of sudden cardiac death and takes a QTc-prolonging antiarrhythmic. Integrating domperidone's central and cardiac profiles, what is the correct reasoning?
A) Domperidone avoids the extrapyramidal problem because it is largely excluded from the CNS, but its propensity to prolong the QTc via hERG channel blockade makes it hazardous in this cardiac context, so a baseline ECG, lowest effective dose, and avoidance of concurrent QTc-prolonging drugs are essential, and it may be inappropriate here
B) Domperidone is the ideal choice because it has no cardiac effects and no central effects of any kind
C) Domperidone should be avoided only because it would, like metoclopramide, cause recurrent dystonia
D) Domperidone crosses the blood-brain barrier even more than metoclopramide, so dystonia is the main concern rather than arrhythmia
E) Domperidone's QTc effect is irrelevant when a patient is already on a QTc-prolonging antiarrhythmic, because the effects do not summate
ANSWER: A
Rationale:
Domperidone is a P-glycoprotein substrate that is largely excluded from the CNS, so it avoids the extrapyramidal effects (including dystonia) seen with metoclopramide. However, its principal liability is QTc prolongation through cardiac hERG channel blockade, which is especially dangerous in a patient with a family history of sudden cardiac death and concurrent use of a QTc-prolonging antiarrhythmic; a baseline ECG, the lowest effective dose, and avoidance of other QTc-prolonging drugs are required, and the agent may be inappropriate in this specific context.
Option B: Option B is incorrect because domperidone does carry a meaningful QTc/arrhythmia risk.
Option C: Option C is incorrect because domperidone does not cause dystonia, given its CNS exclusion.
Option D: Option D is incorrect because domperidone crosses the blood-brain barrier less, not more, than metoclopramide.
Option E: Option E is incorrect because QTc-prolonging effects are additive, so concurrent use heightens rather than nullifies the risk.
8. A hospitalized patient in an acute diabetic gastroparetic crisis needs rapid restoration of gastric emptying, but the team is also planning the outpatient regimen for after discharge. Applying the mechanisms and limitations of the available prokinetics, which plan is most rational?
A) Use oral metoclopramide indefinitely for both the acute crisis and long-term control, because tachyphylaxis is not a concern with any prokinetic
B) Use intravenous erythromycin for both the acute crisis and indefinite long-term outpatient management, because its efficacy is sustained
C) Avoid all prokinetics acutely and rely solely on parenteral nutrition from the outset
D) Use a 5-HT3 antagonist as the prokinetic of choice for the acute crisis
E) Use intravenous erythromycin for its potent acute prokinetic effect during the crisis, recognizing that tachyphylaxis limits its long-term value, and transition to metoclopramide (lowest effective dose, with the 12-week ceiling in mind) for ongoing outpatient management
ANSWER: E
Rationale:
Low-dose erythromycin is among the most potent prokinetics for acute use because it is a motilin receptor agonist driving strong antral contractions, making it well suited to an acute gastroparetic crisis; however, tachyphylaxis from motilin receptor downregulation within days to weeks limits its long-term value. Metoclopramide, the only FDA-approved agent for gastroparesis, is appropriate for ongoing outpatient management at the lowest effective dose with attention to the 12-week tardive dyskinesia ceiling.
Option A: Option A is incorrect because metoclopramide is constrained by its tardive dyskinesia risk and is not ideal as an indefinite sole agent, and tachyphylaxis is relevant to erythromycin.
Option B: Option B is incorrect because erythromycin's prokinetic efficacy wanes with continuous use, so it is not suitable for indefinite management.
Option C: Option C is incorrect because prokinetics and supportive care are first-line, with parenteral nutrition reserved as a last resort.
Option D: Option D is incorrect because 5-HT3 antagonists are antiemetics without prokinetic activity.
9. An elderly patient with angle-closure glaucoma and benign prostatic hyperplasia asks for a scopolamine patch to prevent seasickness on an upcoming cruise. Integrating scopolamine's mechanism with this patient's comorbidities, what is the most appropriate counseling?
A) Scopolamine is ideal here because its anticholinergic activity will improve both glaucoma and prostatic symptoms
B) Scopolamine's antimuscarinic action can precipitate acute angle-closure glaucoma and urinary retention and can cause confusion in elderly patients, so it should be used with great caution or avoided, and an alternative antiemetic should be considered; hands must also be washed after handling the patch to avoid ocular exposure
C) Scopolamine has no anticholinergic effects, so the comorbidities are irrelevant
D) Scopolamine is contraindicated only because it prolongs the QTc interval in elderly patients
E) Scopolamine is safe in angle-closure glaucoma but should be avoided in open-angle glaucoma
ANSWER: B
Rationale:
Scopolamine is a muscarinic antagonist, and its anticholinergic effects (dry mouth, blurred vision, urinary retention, confusion or sedation in the elderly) make it hazardous in this patient: it can precipitate acute angle-closure glaucoma and worsen urinary retention from benign prostatic hyperplasia, and elderly patients are particularly susceptible to confusion. It should therefore be used with great caution or avoided, an alternative considered, and the patient counseled to wash hands after handling the patch to avoid inadvertent ocular exposure that can trigger angle-closure.
Option A: Option A is incorrect because anticholinergic activity worsens, rather than improves, both angle-closure glaucoma and prostatic outflow obstruction.
Option C: Option C is incorrect because scopolamine has prominent anticholinergic effects directly relevant to these comorbidities.
Option D: Option D is incorrect because the concern is anticholinergic toxicity, not QTc prolongation.
Option E: Option E is incorrect because anticholinergic agents are specifically hazardous in angle-closure glaucoma, the opposite of what this option states.
10. A regimen designer wants to simplify antiemetic prophylaxis for moderately-to-highly emetogenic chemotherapy by minimizing the number of separate administrations while still covering both the acute and delayed phases. Integrating palonosetron's pharmacokinetics with combination-product logic, which approach best achieves this?
A) Give multiple daily doses of ondansetron, because its short half-life provides the most durable coverage
B) Use scopolamine plus dexamethasone, since vestibular blockade covers both phases of chemotherapy nausea
C) Use a motilin agonist combined with a muscarinic antagonist to cover both phases
D) Use palonosetron, whose long half-life and high receptor affinity give durable 5-HT3 coverage, ideally as a fixed-dose combination with the NK1 antagonist netupitant (NEPA) so that 5-HT3 and NK1 blockade are delivered together in a single oral administration alongside dexamethasone
E) Use two different first-generation 5-HT3 antagonists together to extend the duration of action
ANSWER: D
Rationale:
Palonosetron has a long half-life (approximately 40 hours) and high receptor binding affinity, giving durable 5-HT3 coverage that extends into the delayed window, and it is available in a fixed-dose combination with the NK1 antagonist netupitant (the NEPA product), which delivers 5-HT3 and NK1 blockade together in a single oral administration; paired with dexamethasone, this minimizes separate administrations while covering both the acute and delayed phases.
Option A: Option A is incorrect because ondansetron's short half-life provides less durable coverage and multiple dosing adds complexity and QTc risk.
Option B: Option B is incorrect because scopolamine targets the vestibular pathway, not the chemotherapy-driven CTZ and NK1 pathways.
Option C: Option C is incorrect because motilin agonists and muscarinic antagonists are not the appropriate agents for chemotherapy-induced nausea coverage.
Option E: Option E is incorrect because combining two first-generation 5-HT3 antagonists does not add NK1 coverage and offers no meaningful pharmacokinetic advantage over a single long-acting agent.
11. A patient is to receive a three-drug regimen for highly emetogenic chemotherapy: a 5-HT3 antagonist, aprepitant, and dexamethasone. Integrating dexamethasone's role with the aprepitant interaction, what is the correct understanding of how dexamethasone fits into the regimen and how it should be dosed?
A) Dexamethasone should be omitted entirely, because it has no antiemetic value when combined with an NK1 antagonist
B) Dexamethasone's dose should be increased above its usual antiemetic dose to overcome aprepitant's enzyme effect
C) Dexamethasone is a well-established antiemetic adjunct that improves complete response rates, and because aprepitant inhibits CYP3A4 and raises dexamethasone exposure, its dose is reduced (to roughly 8 mg) when co-administered with aprepitant
D) Dexamethasone works only on the acute phase and is unnecessary for delayed-phase coverage, so it can be stopped after day 1 regardless of the NK1 antagonist
E) Dexamethasone and aprepitant should never be combined because the interaction is dangerous and unmanageable
ANSWER: C
Rationale:
Dexamethasone is a well-established antiemetic adjunct that improves complete response rates by roughly 15 to 25 percentage points when added to 5-HT3-antagonist-based regimens, and it contributes to both acute and delayed coverage. Because aprepitant is a moderate CYP3A4 inhibitor that raises dexamethasone exposure, the dexamethasone dose is reduced (to approximately 8 mg) when the two are co-administered.
Option A: Option A is incorrect because dexamethasone retains substantial antiemetic value in combination regimens.
Option B: Option B is incorrect because the dose is reduced, not increased, since aprepitant raises dexamethasone levels.
Option D: Option D is incorrect because dexamethasone is continued for delayed-phase coverage in highly emetogenic regimens rather than stopped after day 1.
Option E: Option E is incorrect because the interaction is well characterized and readily managed by a planned dose reduction.
12. A patient with idiopathic gastroparesis has had partial benefit from metoclopramide but is now approaching the 12-week mark and has developed mild restlessness. Applying the stepwise gastroparesis framework, what is the most appropriate next step?
A) Continue metoclopramide indefinitely at a higher dose, since the 12-week limit is only a suggestion
B) Recognize that the akathisia (restlessness) and the approaching 12-week ceiling argue against continued metoclopramide, and step to an alternative such as low-dose erythromycin for exacerbations (anticipating tachyphylaxis) or domperidone where available with a normal baseline QTc, while continuing dietary modification and, in diabetics, glycemic optimization, and considering gastric electrical stimulation referral for refractory symptoms
C) Switch immediately to parenteral nutrition as the next pharmacological step
D) Add a second dopamine D2 antagonist to the metoclopramide to boost the prokinetic effect
E) Discontinue all therapy because no further options exist after metoclopramide
ANSWER: B
Rationale:
The emergence of akathisia together with the approaching 12-week tardive dyskinesia ceiling argues against continuing metoclopramide. The stepwise framework moves to alternatives: low-dose erythromycin for exacerbations (with the understanding that tachyphylaxis limits chronic use), or domperidone where available in a patient with a normal baseline QTc and no QTc-prolonging co-medications, while maintaining dietary modification and, in diabetic patients, glycemic optimization, and considering referral for gastric electrical stimulation in refractory cases.
Option A: Option A is incorrect because the 12-week limit is a black-box safety boundary, and dose escalation in the face of emerging extrapyramidal symptoms is inappropriate.
Option C: Option C is incorrect because parenteral nutrition is a last resort, not the next pharmacological step.
Option D: Option D is incorrect because adding a second D2 antagonist compounds extrapyramidal risk without a sound rationale.
Option E: Option E is incorrect because several further options remain after metoclopramide.
13. A younger oncology patient with both refractory chemotherapy-induced nausea and significant anorexia and weight loss has failed a standard three-drug antiemetic regimen. The team considers dronabinol but is weighing its use carefully. Integrating dronabinol's pharmacology with patient selection, which statement best captures the appropriate reasoning?
A) Dronabinol should be used first-line in place of the three-drug regimen because it is more effective than 5-HT3 and NK1 antagonists
B) Dronabinol is contraindicated in any patient with anorexia because it suppresses appetite
C) Dronabinol acts as a 5-HT3 antagonist and should simply replace ondansetron in the regimen
D) Dronabinol is a CB1 partial agonist with both antiemetic and orexigenic effects, making it a reasonable rescue option in this patient who has refractory nausea and concurrent anorexia, with the caveats that its CNS effects (euphoria or dysphoria, sedation, impaired psychomotor function) are often poorly tolerated, particularly in older adults, and that it is a Schedule III controlled substance
E) Dronabinol's only role is in motion sickness, so it is inappropriate for this patient
ANSWER: D
Rationale:
Dronabinol is a synthetic delta-9-tetrahydrocannabinol that acts as a CB1 (cannabinoid receptor type 1) partial agonist, producing both antiemetic and orexigenic (appetite-stimulating) effects, which makes it a reasonable rescue option for a patient with refractory chemotherapy-induced nausea and concurrent anorexia after failure of standard regimens. Its CNS adverse effects (euphoria or dysphoria, sedation, impaired psychomotor function) are often poorly tolerated, especially in older adults, and it is a Schedule III controlled substance.
Option A: Option A is incorrect because dronabinol is a rescue agent used after standard regimens fail, not a first-line replacement.
Option B: Option B is incorrect because dronabinol stimulates appetite and is in fact useful for anorexia, the opposite of suppression.
Option C: Option C is incorrect because dronabinol acts at CB1 receptors, not 5-HT3 receptors.
Option E: Option E is incorrect because dronabinol's role is in refractory chemotherapy nausea and anorexia, not motion sickness.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.